Substituted pyridines as inhibitors of histone deacetylase

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

13. A method for inhibiting histone deacetylase activity in a subject, wherein the method comprises administering to the subject in need thereof a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

14. A method for treating a condition in a subject, wherein the method comprises administering to the subject in need thereof a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof;

wherein the condition is selected from the group consisting of a cognitive function disorder, a cognitive function impairment, an extinction learning disorder, a fungal disease, a fungal infection, a hematological disease, an inflammatory disease, a memory disorder, a memory impairment, a neoplastic disease, a neurological disorder, and a psychiatric disorder.

15. The method of claim 14 , wherein the condition is:

(a) a cognitive function disorder, a cognitive function impairment, or a psychiatric disorder selected from the group consisting of age related cognitive decline, anxiety disorder, attention deficit disorder, attention deficit hyperactivity disorder, bipolar disorder, a cognitive function disorder associated with Alzheimer's disease, a cognitive function impairment associated with Alzheimer's disease, a cognitive disorder associated with autism, a learning disorder associated with autism, a social disorder associated with autism, conditioned fear response, dyslexia, fragile X syndrome, obsessive compulsive disorder, panic disorder, a phobia, post-traumatic stress disorder, Rubinstein-Taybi syndrome, schizophrenia, social anxiety disorder, and substance dependence recovery; or

(b) an extinction learning disorder selected from the group consisting of fear extinction and post-traumatic stress disorder; or

(c) a hematological disease selected from the group consisting of acute lymphoblastic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, chronic myelogenous leukemia, a myelodysplastic syndrome, and sickle cell anemia; or

(d) a memory disorder, a memory impairment, or a neurological disorder selected from the group consisting of age associated memory impairment, ataxia, frontotemporal dementia, Huntington's disease, Lewy body dementia, Parkinson's disease, Rett syndrome, seizure induced memory loss, traumatic head injury, and vascular dementia; or

(e) a neoplastic disease.

16. The method of claim 14 , wherein the condition is Alzheimer's disease, Freidrich's ataxia, frontotemporal dementia, Huntington's disease, Parkinson's disease, post-traumatic stress disorder, or substance dependence recovery.